10 
Ihis preanble vrould indicate that the IBC is responsible fior assessing 
risks and initiating nedical surveillance practices; the CDC/NICSH document 
outlines a recarmended ^proach for biotechnology medical surveillance when 
ri^ assessment makes such an approach prudent or when risk is unknown. 
Er, Richardson supported Et. Mason’s proposal. ET. Mason then offered a 
notion: that a preamble emphasizing IBC responsibility be added to the CEC/NIOSH 
report. By a vote of fi\^ in favor, none opposed and two abstentions the 
motion was accepted. 
(Later in the meeting Dr. Landrigan read his version of a proposed preamble to 
the CDC/NIOSH report. Et. Mason read his version of a proposed preamble. They 
agreed to discuss the preamble fcy telephone.) 
Presentation by Eli Lilly and Company 
Dr. Mith of Eli Lilly and Company said he would oonmunicate some of Eli Lilly's 
experiences in producing human insulin using an ^ coli K-12 host-vector system. 
Dr. Muth said the concerns and issues faced by the company have charged during 
Eli Lilly's involvemait with recombinant DNA technology, although the primary 
aim of safely scaling up reconbinant organism fermentations to conmercial pro- 
duction has remained the same. Lilly's expertise in the fermentatican industry 
dates back to the 1940 's and primarily involves the use of Streptonyces arx3 
fungi for the marufacture of antibiotics. Although in recent years many tech- 
nical changes have occurred in the age-old process of fermentation, the basic 
principles for fermentaticxi of recombinant DKA organisms are essentially 
the same as those used since the 1940 's for producing antibiotics. Several 
developnent projects using Bacillus and E. coli were Eli Lilly's princip>al 
prior experience in bacterial fermentations. 
[ 496 ] 
